207, Porter St

Boston,

MA,

USA,

ZIP: 02128

Phone: +1 617 455 4188

Are you refining and optimizing your in vivo gene editing delivery strategies for the next generation of gene editors to unlock increased therapeutic efficacy, safety, and cost effectiveness?

Recent clinical trial successes from the likes of Editas Medicine and Tessera Therapeutics have highlighted the importance of targeted delivery for the safety and efficacy of in vivo gene editing. Formulation and delivery experts are uniting to evaluate and optimize cutting edge delivery strategies including LNPs, AAVs, exosomes, peptide shuttles, and polymer nanoparticles at the Gene Editing Delivery Summit. Leverage this insight to supercharge precise and efficient extra-hepatic in vivo gene editing to patients with previously untreatable genetic diseases.

Take advantage of the end-to-end content from discovery, optimization, evaluation, and scale-up topics covered in 2 hands-on workshops and 2 full days of data-driven case studies and discussion sessions from trailblazing drug developers such as Prime Medicine, Beam Therapeutics, Editas Medicine, and AstraZeneca to guide your in vivo gene editing delivery strategies for regulatory approval.

Join us in at the Gene Editing Delivery Summit in October to gain practical insights for your discovery, development, optimization, and engineering of delivery systems for your gene editor of choice for targets beyond the liver to accelerate into the clinic.

URLs:
Tickets: https://go.evvnt.com/1834795-2?pid=1052
Brochure: https://go.evvnt.com/1834795-3?pid=1052

Prices:
Drug Developer - Conference + 2 Workshops: USD 4297.00,
Drug Developer - Conference + 1 Workshop: USD 3648.00,
Drug Developer - Conference Only: USD 2999.00,
Academic and Research - Conference + 2 Workshops: USD 3697.00,
Academic and Research - Conference + 1 Workshop: USD 3148.00,
Academic and Research - Conference Only: USD 2599.00,
Service Provider - Conference + 2 Workshops: USD 5297.00,
Service Provider - Conference + 1 Workshop: USD 4548.00,
Service Provider - Conference Only: USD 3799.00

Anna (Xue) Cheng, Director of R and D Pulmonary Delivery, Feldan Therapeutics, David Guay, Vice President Technology and Innovation, Feldan Therapeutics, Delai Chen, Director of Nanoparticle Formulation, Beam Therapeutics, Jerrin George, HFSP Postdoctoral Fellow, Columbia University Irving Medical Center Sternberg Lab, Jessie Davis, Senior Scientist, Prime Medicine, Joe Nabhan, Chief Scientific Officer, Vesigen Therapeutics, John Zuris, Director of Gene Editing Technologies, Editas Medicine, Katherine Cook, Scientist, Tessera Therapeutics, Kelly Banas, Principal Investigator, ChristianaCare Gene Editing Institute, Marine Hatit, Senior Scientist I – LNP Discovery Lead, Prime Medicine, Nageswara Rao Kollu, Senior Director, Apellis Pharmaceuticals, P.J. Brooks, Acting Director, Division of Rare Disease Research Innovation, NCATS NIH, Robert Bell, Senior Vice President and Head of Research, Ascidian Therapeutics, Roland Baumgartner, Senior Director - Research and Development, Artisan Cells, Saumyaa Saumyaa, Associate Director, AstraZeneca, Sourav Choudhury, Head of AAV Technologies, Sanofi Genomic Medicines Unit, Susan Rosenbaum, Founder, Chairman and Chief Executive Officer, Lauren Sciences LLC, Wes Salomon, Director of Delivery Biology, Tessera Therapeutics